Abstract
Current fibrinolytic regimens fail to fully restore coronary blood flow in slightly less than 50% of patients with acute myocardial infarction. Platelet activation and aggregation may be responsible for a large proportion of these therapeutic failures. Therefore, platelet inhibition may enhance thrombolysis. Experimental and early clinical evidence suggest that glycoprotein IIb/IIIa antagonists may enhance reperfusion when combined with reduced doses of thrombolytic agents. However, the clinical benefit of combination therapy will depend on the outcomes of a number large clinical trials that are currently being performed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 378-385 |
| Number of pages | 8 |
| Journal | Current Cardiology Reports |
| Volume | 2 |
| Issue number | 5 |
| DOIs | |
| State | Published - Dec 1 2000 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine